Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/23006
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartín, Miguel
dc.contributor.authorMartínez, Noelia
dc.contributor.authorRamos, Manuel
dc.contributor.authorCalvo, Lourdes
dc.contributor.authorLluch, Ana
dc.contributor.authorZamora, Pilar
dc.contributor.authorMuñoz, Montserrat
dc.contributor.authorCarrasco, Eva
dc.contributor.authorCaballero, Rosalía
dc.contributor.authorGarcía-Sáenz, José Ángel
dc.contributor.authorGuerra, Eva
dc.contributor.authorCaronia, Daniela
dc.contributor.authorCasado, Antonio
dc.contributor.authorRuíz-Borrego, Manuel
dc.contributor.authorHernando, Blanca
dc.contributor.authorChacón, José Ignacio
dc.contributor.authorDe la Torre-Montero, Julio César
dc.contributor.authorJimeno, María Ángeles
dc.contributor.authorHeras, Lucía
dc.contributor.authorAlonso, Rosario
dc.contributor.authorDe la Haba, Juan
dc.contributor.authorPita, Guillermo
dc.contributor.authorConstenla, Manuel
dc.contributor.authorGonzález-Neira, Anna
dc.date.accessioned2019-06-28T13:47:49Z-
dc.date.available2019-06-28T13:47:49Z-
dc.date.issued2015-02
dc.identifier.citationOncologist.2015 Feb;(20)2:111-2
dc.identifier.urihttps://hdl.handle.net/20.500.12530/23006-
dc.description.abstractThe approved capecitabine regimen as monotherapy in metastatic breast cancer (MBC) is 1,250 mg/m(2) twice daily for 2 weeks on and 1 week off (Cint). Dose modifications are often required because of severe hand-foot syndrome (HFS). We tested a continuous regimen with a lower daily dose but a similar cumulative dose in an attempt to reduce the severity of adverse events (AEs) while maintaining efficacy.
dc.language.isoeng
dc.rightsopenAccess-
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBreast Neoplasms
dc.subject.meshCapecitabine
dc.subject.meshDisease-Free Survival
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshHand-Foot Syndrome
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshTreatment Outcome
dc.subject.meshPharmacogenetics
dc.titleStandard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.
dc.typeArtículo
dc.identifier.pubmedID25601966
dc.format.volume20
dc.format.page111-2
dc.identifier.e-issn1549-490X
dc.identifier.journalThe oncologist
dc.identifier.doi10.1634/theoncologist.2014-0379
dc.format.number2
dc.identifier.pmcPMC4319639
dc.pubmedtypeClinical Trial, Phase II
dc.pubmedtypeJournal Article
dc.pubmedtypeRandomized Controlled Trial
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC4319639.pdf665.98 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.